RPI ID: 2024-030-201
Innovation Summary: This technology introduces a bead-based assay platform designed to screen for inhibitors of protein-glycan interactions implicated in neurodegenerative diseases. The assay utilizes functionalized beads to capture glycan-binding proteins and assess their interaction dynamics in the presence of candidate inhibitors. It enables high-throughput screening with enhanced sensitivity and specificity. The system is optimized for identifying therapeutic leads targeting glycan-mediated pathways in neurological disorders.
Challenges / Opportunities: Protein-glycan interactions play a critical role in neurodegeneration, but current screening methods are limited in throughput and resolution. This invention addresses the need for scalable, precise assays to identify inhibitors that can modulate these interactions. It opens opportunities for drug discovery in Alzheimer’s, Parkinson’s, and other neurodegenerative conditions. The platform also supports biomarker development and mechanistic studies of glycan biology.
Key Benefits / Advantages: ✔ High-throughput screening capability ✔ Enhanced sensitivity for detecting protein-glycan interactions ✔ Enables identification of therapeutic inhibitors ✔ Applicable to multiple neurodegenerative disease models ✔ Supports biomarker discovery and mechanistic research
Applications: • Drug discovery for neurodegenerative diseases
Keywords: Protein-glycan interactions, neurodegeneration, bead-based assay, inhibitor screening, glycomics, therapeutic discovery
Intellectual Property: US20250189533A1 (Application 18/977315), Published December 11, 2024